Keywords: Nycomed, Third quarter 2009 results, Pantoprazole, Daxas

Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales

Article | 13 November 2009

• Print This

Privately-owned Swiss prescription and over-the-counter drugmaker Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing 0.9% (3.2% in local currencies) to 820.0 million euros ($1.22 billion).
S
ales of its gastrointestinal drug pantoprazole were resilient after losing patent protection in May in 12 European countries, falling just 15.7% to 272.8 million euros. Moreover, the company noted, OTC variants of the drug were performing well in Europe. On a regional basis, group sales in most emerging markets exhibited strong growth. Adjusted EBITDA decreased 3.1% (1.5% in local currencies) to 285.3 million euros.

The firm said its pipeline portfolio had advanced significantly. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.